This site is intended for Healthcare professionals only.

Gilead’s three-drug HIV regimen wins European panel approval


Gilead’s three-drug HIV regimen wins European panel approval

Gilead Sciences Inc said its three-drug regimen to treat HIV infection was recommended for approval by a panel of the European Medicines Agency, paving the way for the biotech company to capture more sales in the multibillion-dollar market.

The Committee for Medicinal Products for Human Use (CHMP) backed the treatment, Biktarvy, a once-daily tablet that combines two previously approved drugs – emtricitabine, tenofovir alafenamide and a new integrase inhibitor bictegravir.

The CHMP opinion sets the stage for a likely approval by the European Commission.
The combination, which was approved by the U.S. Food and Drug Administration in February, faced criticism from rival ViiV Healthcare, a joint venture majority-owned by GlaxoSmithKline Plc with Pfizer Inc and Shionogi Ltd.
The joint venture filed a lawsuit soon after the U.S. regulator’s approval alleging that Gilead was infringing patents on ViiV’s dolutegravir, a component of the company’s triple-drug HIV treatment Triumeq.

(Reporting By Justin George Varghese in Bengaluru; Editing by Bernard Orr)



Source: REUTERS
0 comment(s) on Gilead’s three-drug HIV regimen wins European panel approval

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted